|
Synonyms: colony-stimulating factor | CSF
Compound class:
Endogenous peptide in human, mouse or rat
Comment: GM-CSF as a target in inflammatory/autoimmune disease was reviewed by Hamilton (2015) [3].
COVID-19: In March 2021, results of the analysis of the inflammatory cytokine/chemokine profiles from COVID-19 patients (spanning the spectrum from mild to fatal disease) and archival samples from patients with severe influenza, identified elevated GM-CSF as a principal marker of severe COVID-19 immunopathology. Both IL-6 and GM-CSF elevations were detected as potent drivers of COVID-19 pathogenesis (associated with disease severity and coinciding with elevated markers of endothelial injury and thrombosis), GM-CSF distinguished COVID-19 from fatal influenza [8]. The findings from this study supports continued targeting of GM-CSF as a therapy for patients with severe COVID-19. Investigational anti-GM-CSF monoclonals that were repositioned for COVID-19 and entered into clinical trials in COVID-19 positive patients include lenzilumab, gimsilumab, otilimab and plonmarlimab [2].
Species: Human
|
Classification  |
|
| Compound class | Endogenous peptide in human, mouse or rat |
| Synonyms |
| colony-stimulating factor | CSF |
| Gene/Precursor |
||||||||||
|
| Database Links |
|
| Ensembl Gene | ENSG00000164400 (Hs) |
| GtoPdb PubChem SID | 178101640 |
| Human Protein Atlas | ENSG00000164400 (Hs) |
| UniProtKB | P04141 (Hs) |
| Wikipedia | Granulocyte_macrophage_colony-stimulating_factor |
